E-LIB Suche - Ergebnisse für: Michalska, Margaret

1

Treatment Patterns, Disease Burden, and Outcomes in Patient..:

Craig, Gary ; Knapp, Keith ; Salim, Bob..
Rheumatology and Therapy. 8 (2021) 1 - p. 529-539 , 2021

Link: https://doi.org/10.1007/..

2

Phase IIa Global Study Evaluating Rituximab for the Treatme..:

Brogan, Paul ; Yeung, Rae S. M. ; Cleary, Gavin...
Arthritis & Rheumatology. 74 (2021) 1 - p. 124-133 , 2021

Link: https://doi.org/10.1002/..

3

286. RISK OF POTENTIAL GLUCOCORTICOID-RELATED ADVERSE EVENT..:

Best, Jennie ; Kong, Amanda ; Tran, Oth.
Rheumatology. 58 (2019) Supplement_2 - p. , 2019

Link: https://doi.org/10.1093/..

4

Healthcare Costs of Potential Glucocorticoid-Associated Adv..:

Best, Jennie H ; Kong, Amanda M ; Smith, David M..
ClinicoEconomics and Outcomes Research. 11 (2019) - p. 799-807 , 2019

Link: https://doi.org/10.2147/..

5

Risk of Potential Glucocorticoid-Related Adverse Events in ..:

Best, Jennie H. ; Kong, Amanda M. ; Unizony, Sebastian..
Rheumatology and Therapy. 6 (2019) 4 - p. 599-610 , 2019

Link: https://doi.org/10.1007/..

6

Sustained Response Following Discontinuation of Methotrexat..:

Kremer, Joel M. ; Rigby, William ; Singer, Nora G....
Arthritis & Rheumatology. 70 (2018) 8 - p. 1200-1208 , 2018

Link: https://doi.org/10.1002/..

7

Impact of tocilizumab administered intravenously or subcuta..:

Strand, Vibeke ; Michalska, Margaret ; Birchwood, Christine...
RMD Open. 4 (2018) 1 - p. e000602 , 2018

Link: https://doi.org/10.1136/..

8

Costs of Disease Relapses Among Individuals with Granulomat..:

Kong, Amanda M. ; Kim, Gilwan ; Michalska, Margaret.
Rheumatology and Therapy. 5 (2018) 1 - p. 159-170 , 2018

Link: https://doi.org/10.1007/..

9

Impact of tocilizumab monotherapy on patient-reported outco..:

Strand, Vibeke ; Michalska, Margaret ; Birchwood, Christine...
RMD Open. 3 (2017) 2 - p. e000496 , 2017

Link: https://doi.org/10.1136/..

10

Phase IIa Global Study Evaluating Rituximab for the Treatme..:

Brogan, Paul ; Yeung, Rae S. M ; Cleary, Gavin...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299798/. , 2021

Link: http://www.ncbi.nlm.nih...

11

Healthcare Costs of Potential Glucocorticoid-Associated Adv..:

Best, Jennie H ; Kong, Amanda M ; Smith, David M..
info:eu-repo/semantics/altIdentifier/doi/10.2147/CEOR.S228400. , 2019

Link: https://www.dovepress.co..

12

Healthcare Costs of Potential Glucocorticoid-Associated Adv..:

Best, Jennie H ; Kong, Amanda M ; Smith, David M..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934125/. , 2019

Link: http://www.ncbi.nlm.nih...

13

Costs of Disease Relapses Among Individuals with Granulomat..:

Kong, Amanda M ; Kim, Gilwan ; Michalska, Margaret.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935630/. , 2018

Link: http://www.ncbi.nlm.nih...

14

RMD Open / Impact of tocilizumab administered intravenously..:

Kivitz, Alan J ; Smolen, Josef S ; Strand, Vibeke...
vignette : https://repositorium.meduniwien.ac.at/titlepage/urn/urn:nbn:at:at-ubmuw:3-44634/128. , 2018

Link: https://doi.org/10.1136/..

15

Impact of tocilizumab monotherapy on patient-reported outco..:

Strand, Vibeke ; Michalska, Margaret ; Birchwood, Christine...
info:eu-repo/semantics/altIdentifier/doi/10.1136/rmdopen-2017-000496. , 2017

Link: https://archive-ouverte...